Adamis Pharmaceuticals

Adamis Pharmaceuticals R&D per Employee

Delisted

The R&D Spending per Employee of Adamis Pharmaceuticals (ADMP) as of Nov 15, 2026 is 79,236.37 USD. In the previous year, R&D Spending per Employee was 85,972.31 USD — a change of -7.84% (lower).

R&D per Employee

79,236.37USD

YoY

-7.84%

Last updated:

R&D Spending per Employee of Adamis Pharmaceuticals is 2022 79,236.37 USD. R&D Spending per Employee of Adamis Pharmaceuticals was 2021 85,972.31 USD. It decreases by -7.84% lower compared to the previous year.

The Adamis Pharmaceuticals R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2015
36,970.53 USD
Jan 1, 2016
74,023.94 USD
Jan 1, 2017
57,456.37 USD
Jan 1, 2018
143,464.40 USD
Jan 1, 2019
79,206.04 USD
Jan 1, 2020
63,211.83 USD
Jan 1, 2021
85,972.31 USD
Jan 1, 2022
79,236.37 USD
The Adamis Pharmaceuticals R&D per Employee history
YEARR&D per EmployeeYoY
79,236.37USD-7.84%
85,972.31USD+36.01%
63,211.83USD-20.19%
79,206.04USD-44.79%
143,464.40USD+149.69%
57,456.37USD-22.38%
74,023.94USD+100.22%
36,970.53USD+36.60%
27,064.73USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adamis Pharmaceuticals Stock analysis

What does Adamis Pharmaceuticals do? Adamis Pharmaceuticals Corp is a biotechnology company based in the USA that specializes in the development of pharmaceuticals and medical devices. The company was founded in 2006 and is headquartered in San Diego, California. History: Adamis Pharmaceuticals was founded by Dr. Dennis J. Carlo, an experienced pharmaceutical executive with over 35 years of industry experience. The company initially focused on the development of therapeutics for the treatment of allergies and respiratory diseases. Over the years, the company has expanded its portfolio and specialized in the development of drugs for the treatment of anaphylaxis, asthma, and prostate cancer, as well as medical devices for drug delivery. Business model: Adamis Pharmaceuticals focuses on the development of novel drugs and medical devices that can improve patients' lives. The company seeks opportunities to meet unmet medical needs in existing therapy areas. Adamis collaborates closely with leading medical institutions and research facilities to develop and market a portfolio of innovative products. Various divisions: The company has various divisions, including: 1. Allergy/Respiratory: Adamis Pharmaceuticals has developed a broad portfolio of therapeutic agents for the treatment of allergies and respiratory diseases. The company has also developed a patented device called Symjepi, which is used to treat anaphylaxis, a life-threatening allergic reaction. This device also allows untrained individuals to self-treat in an anaphylaxis situation. 2. Oncology: Adamis Pharmaceuticals has developed a novel drug called TeloBlast®, which is used to treat prostate cancer. TeloBlast® targets telomerase, which is upregulated in many types of cancer. The company intends to develop additional drugs for the treatment of cancer in the future. 3. CNS: Adamis Pharmaceuticals has also developed innovative drugs for the treatment of CNS (central nervous system) disorders. The company plans to bring several new drugs for the treatment of neurological disorders to the market by 2022. 4. Medical devices: Adamis Pharmaceuticals has developed a range of patented medical devices, including the ZIM high-pressure injection pump, which allows doctors and nurses to administer medications quickly and accurately. Products: Adamis Pharmaceuticals' products include: 1. Symjepi: A patented device for the treatment of anaphylaxis. 2. TeloBlast®: A novel drug for the treatment of prostate cancer. 3. ZIM high-pressure injection pump: A patented medical device for drug administration. 4. Fluticasone/Salmeterol: An inhalable combination drug for the treatment of asthma and COPD (chronic obstructive pulmonary disease). Adamis Pharmaceuticals is an innovative biotechnology company specializing in the development of pharmaceuticals and medical devices. The company aims to meet unmet medical needs and improve patients' lives. With a broad portfolio of products and a strong commitment to research and development, Adamis Pharmaceuticals is well positioned to continue growing in the future. Adamis Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adamis Pharmaceuticals stock

R&D Spending per Employee of Adamis Pharmaceuticals is 79,236.37 USD in 2022.

R&D Spending per Employee of Adamis Pharmaceuticals changed from 85,972.31 USD to 79,236.37 USD, representing a -7.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Adamis Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Adamis Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Adamis Pharmaceuticals

All Key Metrics — Adamis Pharmaceuticals